Off-Label Drug Use: EMA Safety Monitoring and Reporting Requirements

Off-label prescribing is common in clinical practice, but it can create important safety monitoring and reporting considerations for EU pharmacovigilance teams.

What Is Off-Label Use?

About 1 in 5 prescriptions are for off-label drug use, highlighting how common this practice is in healthcare. Under EU GVP, off-label use refers to situations where a medicine is intentionally used outside the terms of its authorised product information, including an unapproved indication, population, dose, or route of administration.

Common Examples of Off-Label Drug Use

Such prescribing may involve a non-authorised indication, a non-authorised patient population, a different dose, or a different route or site of administration. It can also include use in a non-authorised paediatric age category. In a prospective neonatal intensive care study, over 96% of neonates received at least one off-label medication, which accounted for nearly half of all prescribed medication items.

Off-Label Use in the EU Pharmacovigilance Framework

This practice can provide therapeutic options when standard treatments fail or no suitable authorised treatment exists. So, off-label prescribing is part of clinical practice. But pharmacovigilance obligations focus on identifying, assessing, and reporting safety information arising from such use. MAHs must consider new information that may affect the medicine’s benefit-risk balance.

Off-Label Use vs Medication Error, Misuse, and Abuse

Use outside authorised terms is intentional, whereas a medication error involves an unintentional mistake in prescribing, dispensing, or administration. Misuse generally refers to intentional inappropriate use, while abuse involves intentional excessive use that may cause harmful effects. These distinctions matter when assessing and coding safety cases.

Are Adverse Reactions From Off-Label Use Reportable in the EU?

Yes. A suspected ADR associated with off-label exposure may be reportable when the case meets the criteria for a valid ICSR. Pharmacovigilance teams should capture the circumstances of the exposure, including the indication, patient population, dose, dosage form, route, and reason for the off-label drug use. Case validation should establish the minimum information required for processing, while follow-up may clarify missing clinical details. The case should also be assessed for seriousness and clinical outcome. Where reporting criteria are met, the case should be handled in accordance with applicable EU pharmacovigilance requirements and documented within the company’s ICSR management process.

What Information Should Be Captured in the ICSR?

An ICSR should capture patient and reporter details, the suspected medicine, indication, dose, and route of administration. It should also include exposure circumstances, relevant medical conditions, the adverse event, seriousness, clinical outcome, and follow-up information. Any details explaining the off-label medication should also be documented clearly.

Does Off-Label Use Without an ADR Need to Be Reported to EudraVigilance?

Off-label prescribing without a suspected ADR does not automatically constitute an individual case requiring submission to EudraVigilance. However, relevant safety information arising from such use may still require collection, assessment, and monitoring when it could affect the medicine’s benefit-risk balance. MAHs should evaluate information from healthcare providers, patients, research, and other sources to determine whether it reveals a potential safety concern or requires further pharmacovigilance action.

How Is Off-Label Use Addressed in the EU Risk Management Plan?

The RMP may address risks associated with off-label drug use through additional pharmacovigilance activities, risk minimisation measures, and ongoing benefit-risk evaluation. Regulatory intelligence can help teams identify relevant regulatory developments.

When Does Such a Use Become a Safety Concern?

A safety concern may arise when exposure reveals a new or increased risk, unexpected adverse reactions, or a pattern that may alter the medicine’s established safety profile. Particular attention may be warranted when use involves children, a different dose, a different disease, or a population not adequately represented in clinical trials.

Pharmacovigilance Activities for Monitoring Off-Label Use

Monitoring may involve spontaneous reports, medical literature, healthcare provider information, drug utilisation data, and other real-world sources. Teams can evaluate emerging evidence, conduct follow-up, assess potential signals, and update safety information or risk minimisation measures when the evidence supports further action.

How Should MAHs Monitor Off-Label Use?

MAHs should use a risk-based workflow that combines multiple safety data sources, identifies relevant patterns, validates cases, and assesses whether emerging information requires regulatory or risk management action. Pharmaceutical companies generally cannot lawfully promote medicines for unapproved uses, but they still need to monitor safety information arising from such use.

Spontaneous Reports and EudraVigilance

Spontaneous reports can provide important information about adverse reactions following off label medication use. PV teams should review reports for the indication, patient population, dose, route, and other relevant circumstances. EudraVigilance data can support broader safety assessment, helping identify recurring patterns across cases and populations.

Medical Literature Monitoring

Medical literature can reveal safety information that may not be captured by spontaneous reporting. Regular medical literature monitoring should cover relevant publications describing prescription drugs, suspected adverse reactions, and unapproved use. Screening should consider different indications, patient groups, dosage forms, and routes of administration to identify potentially reportable cases and emerging safety concerns.

Drug Utilisation and Other Real-World Data

Drug utilisation data and other real-world evidence can help MAHs understand how medicines are actually used across different populations. These sources may identify use outside approved treatments, unusual prescribing patterns, or exposure involving adults and children. Such information can support safety assessment, signal detection, and evaluation of whether additional guidance or risk minimisation is needed.

Botulinum Toxin: A Recent Example of Off-Label Use as a Safety Consideration

DrugCard’s literature monitoring identified a July 2026 MHRA Drug Safety Update highlighting important safety considerations associated with botulinum toxin products.

What the MHRA Identified

The MHRA reported cases of iatrogenic botulism following therapeutic or cosmetic use of botulinum toxin products. The update notes that risk may increase with high doses, use outside licensed indications, administration to unapproved sites, or use of counterfeit or unauthorised products. Product information is being strengthened accordingly.

What This Example Shows for EU Pharmacovigilance Teams

This example demonstrates the value of monitoring regulatory publications alongside scientific literature. A relevant MHRA safety communication can provide new information about an identified risk and the circumstances of exposure that may warrant assessment by EU pharmacovigilance teams. Such findings can support ongoing safety monitoring, signal assessment, and evaluation of the medicine’s benefit-risk balance within the EU framework.

Can Off-Label Use Generate a Safety Signal?

Yes. Patterns of adverse reactions associated with off-label drug use can contribute to a safety signal when they suggest a new or changing risk. PV teams should assess the strength and consistency of the evidence, relevant patient characteristics, exposure circumstances, and clinical outcomes. Information from spontaneous reports, literature, real-world data, and regulatory communications can be considered together. Effective signal management helps determine whether further investigation or risk minimisation action is warranted.

Key Responsibilities for EU Pharmacovigilance Teams

EU pharmacovigilance teams should identify relevant safety information, distinguish prescribing outside authorised terms from other special situations, validate and process applicable ICSRs, conduct appropriate follow-up, and assess emerging signals. They should also document decisions, maintain regulatory compliance, communicate relevant findings internally, and ensure that significant new information is reflected in ongoing benefit-risk assessment and applicable risk management activities.

Conclusion

Off-label use is not inherently a safety issue, but it can generate important safety information. Systematic monitoring, appropriate case assessment, and timely evaluation help MAHs identify emerging risks and maintain an up-to-date benefit-risk profile.

Frequently Asked Questions

Is off-label use reportable to EudraVigilance?

Use outside authorised terms alone is not automatically an individual case requiring submission. Relevant safety information should be assessed to determine whether it meets reporting criteria or may affect the medicine’s benefit-risk balance.

Are ADRs associated with off-label use reportable?

A suspected ADR associated with such prescribing may be reportable when the case meets applicable ICSR criteria. The circumstances of exposure should be documented, and the case assessed for seriousness and clinical outcome.

Is off-label use the same as a medication error?

No. Off-label drug use is intentional use outside authorised terms, while a medication error involves an unintentional mistake in prescribing, dispensing, or administering a medicine. They are distinct pharmacovigilance special situations.